Literature DB >> 15681912

Viral hepatitis in minority America.

Renard A Rawls1, Kenneth J Vega.   

Abstract

Viral hepatitis continues as an important public health concern in the United States. Available data indicate that acute and chronic viral hepatitis remains an important cause of morbidity and mortality in this country despite the availability of immunization for hepatitis A and B and pharmacologic therapy for chronic hepatitis B and C. Minority populations within the United States are disproportionately affected by acute and chronic viral hepatitis. Many diseases, for example, Barrett's esophagus, affect ethnic groups differently. Viral hepatitis A, B, and C may demonstrate ethnic variation with regard to their epidemiology, natural history, clinicopatholgic findings, complications, and treatment outcomes. This report will review the literature regarding these areas in hepatitis A, B, and C among the African American, Hispanic American, and Native American populations of the United States.

Entities:  

Mesh:

Year:  2005        PMID: 15681912

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  9 in total

1.  Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease.

Authors:  Hashem El-Serag; Katherine A McGlynn; Garth N Graham; Samuel So; Charles D Howell; Ted Fang; Janelle Tangonan Anderson; Thelma King Thiel
Journal:  J Fam Pract       Date:  2010-04       Impact factor: 0.493

2.  Prevalence and correlates of Hepatitis C among injection drug users: The significance of duration of use, incarceration and race/ethnicity.

Authors:  William W Latimer; Sarra L Hedden; Leah Floyd; April Lawson; Alexander Melnikov; S Geoffrey Severtson; Anne-Gloria Moleko; Kristin Cole
Journal:  J Drug Issues       Date:  2009-09

3.  Hospital-Based Hepatitis C Screening of Baby Boomers in a Majority Hispanic South Texas Cohort: Successes and Barriers to Implementation.

Authors:  Barbara S Taylor; Joshua T Hanson; Poornachand Veerapaneni; Roberto Villarreal; Kristin Fiebelkorn; Barbara J Turner
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

4.  Advances in the Treatment of Hepatitis B and Hepatitis C Nonresponders: A Report of Symposia Presented at the 15th Conference of the Asian Pacific Association for the Study of the LiverAugust 18-21, 2005Bali, Indonesia.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

5.  Age cohort differences in illicit drug use and hepatitis C among African American substance users.

Authors:  Nicole Ennis Whitehead; Lauren Hearn; Rebecca C Trenz; Larry E Burrell; William W Latimer
Journal:  J Addict Dis       Date:  2014

6.  Health disparities in liver disease: Time to take notice and take action.

Authors:  Jennifer Guy; Hal F Yee
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

7.  Prevalence of HCV risk factors in Hispanic-American sub populations.

Authors:  Stacey B Trooskin; Maricruz Vega; Steven K Herrine; A Scott McNeal; Robert J Winn; David J Axelrod; Victor J Navarro
Journal:  J Immigr Minor Health       Date:  2010-12

8.  Risk factors associated with Hepatitis C among female substance users enrolled in community-based HIV prevention studies.

Authors:  Diana Nurutdinova; Arbi B Abdallah; Susan Bradford; Catina C O'Leary; Linda B Cottler
Journal:  BMC Res Notes       Date:  2011-04-14

9.  Seroprevalence of Hepatitis B and C Infections among Healthy Volunteer Blood Donors in the Central California Valley.

Authors:  Muhammad Y Sheikh; Pradeep R Atla; Adnan Ameer; Humaira Sadiq; Patrick C Sadler
Journal:  Gut Liver       Date:  2012-12-14       Impact factor: 4.519

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.